Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tahereh Damghani

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Frontiers in Chemistry|December 5, 2022
Study of the anticancer effect of new quinazolinone hydrazine derivatives as receptor tyrosine kinase inhibitorsMotahareh Mortazavi, Masoumeh Divar, Tahereh Damghani, et al.
Scientific Reports|February 12, 2021
Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-MetTahereh Damghani, Fatemeh Moosavi, Mehdi Khoshneviszadeh, et al.
Bioorganic & Medicinal Chemistry|June 22, 2023
Novel spiroindoline quinazolinedione derivatives as anticancer agents and potential FLT3 kinase inhibitorsMasoumeh Divar, Najmeh Edraki, Tahereh Damghani, et al.
European Journal of Pharmacology|November 21, 2022
Discovery of anticancer agents with c-Met inhibitory potential by virtual and experimental screening of a chemical libraryMotahareh Mortazavi, Elaheh Raufi, Tahereh Damghani, et al.
Journal of Medicinal Chemistry|August 13, 2025
Profiling and Optimizing Targeted Covalent Inhibitors through EGFR-Guided StudiesTahereh Damghani, Surbhi P Chitnis, Omobolanle A Abidakun, et al.
Research Square|October 4, 2023
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitorsDavid Heppner, Florian Wittlinger, Blessing Ogboo, et al.
Communications Chemistry|February 20, 2024
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitorsFlorian Wittlinger, Blessing C Ogboo, Ekaterina Shevchenko, et al.
Journal of Medicinal Chemistry|December 3, 2024
Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent "Type V" Kinase InhibitorsFlorian Wittlinger, Surbhi P Chitnis, Calvin D Pham, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Frontiers in Chemistry|December 5, 2022
Study of the anticancer effect of new quinazolinone hydrazine derivatives as receptor tyrosine kinase inhibitorsMotahareh Mortazavi, Masoumeh Divar, Tahereh Damghani, et al.
Scientific Reports|February 12, 2021
Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-MetTahereh Damghani, Fatemeh Moosavi, Mehdi Khoshneviszadeh, et al.
Bioorganic & Medicinal Chemistry|June 22, 2023
Novel spiroindoline quinazolinedione derivatives as anticancer agents and potential FLT3 kinase inhibitorsMasoumeh Divar, Najmeh Edraki, Tahereh Damghani, et al.
European Journal of Pharmacology|November 21, 2022
Discovery of anticancer agents with c-Met inhibitory potential by virtual and experimental screening of a chemical libraryMotahareh Mortazavi, Elaheh Raufi, Tahereh Damghani, et al.
Journal of Medicinal Chemistry|August 13, 2025
Profiling and Optimizing Targeted Covalent Inhibitors through EGFR-Guided StudiesTahereh Damghani, Surbhi P Chitnis, Omobolanle A Abidakun, et al.
Research Square|October 4, 2023
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitorsDavid Heppner, Florian Wittlinger, Blessing Ogboo, et al.
Communications Chemistry|February 20, 2024
Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitorsFlorian Wittlinger, Blessing C Ogboo, Ekaterina Shevchenko, et al.
Journal of Medicinal Chemistry|December 3, 2024
Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent "Type V" Kinase InhibitorsFlorian Wittlinger, Surbhi P Chitnis, Calvin D Pham, et al.
Pageof 2